Lung Cancer Treatment Market Size & Share 2023 to 2032

Lung Cancer Treatment Market Size

Lung Cancer Treatment Market size was valued at USD 15.70 billion in 2022, and it is predicted to increase at a CAGR of 12.4% from 2023 and 2032 owing to rising demand for targeted therapies and increasing incidences of lung cancer across the globe.

Lung cancer is one of the most common type of cancer and accounts for a significant number of cancer related deaths worldwide. Therefore, prevalence of lung cancer diseases is the major driver for the market. According to the International Agency for Research on Cancer's GLOBOCAN 2020 data, there were around 19.3 million new cases of cancer reported in 2020, with lungs cancer accounting for around 11.4%. The number of new cases of lung, trachea, and bronchus cancer in 2020 was estimated to be 2.21 million and is expected to reach 3.63 million by 2040.
 

Lung cancer was the most common cause of death in 2020, accounting for over 18% of all deaths worldwide (1.8 million). Due to the increased frequency of smoking and second-hand smoke exposure, the global incidence of lung cancer is rapidly increasing.

COVID-19 Impact

The COVID-19 pandemic had a slightly negative influence on all elements of oncology therapy and research since screening and cancer care services have been shown to be very low in many nations across the world due to the huge patient pool of covid-19. Moreover, cancer patients were at a greater chance of developing the coronavirus infection, which generated extra health concerns. Due to the limitations on the movement of persons and commodities imposed by governmental and private entities, the supply chain for pharmaceutical products and ingredients has been considerably affected. However, the decline in instances has aided the business in regaining its pre-covid momentum.
 

Lung Cancer Treatment Market Trends

Increasing use of combination therapy in oncology treatment is the current trend. Combination therapies involve using multiple treatments such as chemotherapy and immunotherapy, to improve outcomes in lung cancer patients. This approach has shown promising results in clinical trials and is expected to become more widely used in the coming years. For example, the combination of the chemotherapy drug cisplatin with the immunotherapy drug pembrolizumab has been shown to be effective in treating non-small cell lung cancer (NSCLC).
 

Lung Cancer Treatment Market Analysis

Based on type, the lung cancer treatment market is segmented as non-small cell lung cancer, small cell lung cancer, and carcinoid. The non-small cell lung cancer (NSCLC) segment held the largest revenue share in 2022. One of the major drivers for the non-small cell lung cancer (NSCLC) is the availability and effectiveness of targeted therapy for NSCLC treatment. Targeted therapies are drugs that are meant to target specific genetic alterations that are implicated in cancer cell growth and distribution. They are typically more effective and less toxic than traditional chemotherapy. For example, drugs such as Osimertinib and crizotinib used in targeted therapies that have been approved for the treatment of non-small cell lung cancer with specific genetic mutations.
 

According to the American Cancer Society, 236,740 lung and bronchus cancers are likely to be diagnosed in the United States in 2022, with 130,180 deaths. NSCLC is expected to account for about 85% of those cases. Hence, this is likely to create demand for lung cancer treatment over the forecast period.
 

Based on therapy segment, the lung cancer treatment market is segmented as radiation therapy, immunotherapy, targeted therapy, and chemotherapy, and other therapies. The targeted therapy segment had the highest revenue share of 36.6% in 2022. Targeted therapy is a form of personalised medicine, as it is designed to treat patients with specific genetic mutations or abnormalities. This approach allows physicians to tailor treatment to individual patients which can lead to better outcomes. Moreover, several targeted therapy drugs have been approved for the treatment of non-small cell lung cancer, including drugs such as or osimertinib, crizotinib, and alectinib. These drugs have been shown to be effective in treating NSCLC with specific genetic mutations which has led to increased adoption of targeted therapy in clinical practice. These factors are expected to foster the segment growth.
 

Based on end-user, the lung cancer treatment market is segmented as hospitals, specialty clinics, and other end-users. The hospitals segment is anticipated to grow at 12.1% CAGR by 2032. The development of new technologies and treatments for cancer has led to increased demand for cancer care services in hospitals. Hospitals have access to advanced diagnostic tools, such as emerging technologies and genetic testing and are equipped to provide a wide range of cancer treatments, including surgery, radiation therapy chemotherapy, and immunotherapy.
 

North America lung cancer treatment market was valued at USD 15.70 billion in 2022, and it is predicted to increase at a CAGR of 12.4% from 2023 and 2032 owing to rising demand for targeted therapies and increasing incidences of lung cancer across the globe.  has the highest revenue of 7.17 billion in 2022. North America accounted for significant market in lung cancer treatment and there are several factors that contribute its growth and development, owing to growing aging population, technological advancements for lung cancer treatment, and reimbursement policies for lung cancer treatment. The prevalence of lung cancer is increasing in North America which is pushing demand for lung cancer treatment.
 

According to the American Cancer Society lung cancer is the second most common cancer in both men and women in the United States. Moreover, government in North America are investing in cancer research and treatment, which is driving the development of new therapies and treatments for lung cancer. Additionally, Government funded programs provide access to lung cancer screening and early detection programs which provide outcomes for patients with lung cancer.
 

Lung Cancer Treatment Market Share

Some of the major market players operating in the lung cancer treatment market are :

• Merck KGaA
• ONO PHARMACEUTICAL CO., LTD.
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc.
• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• AstraZeneca
• Takeda Pharmaceutical Company Limited
• Church & Dwight Co., Inc.
• Sun Pharmaceutical Industries Ltd.

These players focus on strategic partnerships, new product launch & commercialization for market expansion. Furthermore, these players are heavily investing in research that allows them to introduce innovative products and garner maximum revenue in the market.
 

Lung Cancer Treatment Market, Industry News:

• In January 2023, Merck & Co., Inc., announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck's anti-PD-1 therapy, as a single agent for adjuvant treatment following surgical resection and platinum-based chemotherapy for adult patients with stage IB (T2a 4 centimetres [cm]), II, or IIIA non-small cell lung cancer (NSCLC).
   
• In May 2021, The U.S. Food and Drug Administration (FDA) approved Lumakras (sotorasib) as the first therapy for adult non-small cell lung cancer patients who have undergone at least one prior systemic therapy and whose tumours exhibit the particular genetic mutation known as KRAS G12C. This is the first FDA-approved targeted treatment for tumours with any KRAS mutation, which accounts for around 25% of non-small cell lung cancer mutations.
   

Lung cancer treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments:

Click here to Buy Section of this Report

By type, 2018 - 2032 (USD Million)

• Non-small cell lung cancer            
• Small cell lung cancer                   
• Carcinoid

By Therapy, 2018 - 2032 (USD Million)

• Radiation Therapy    
  • External beam
  • Internal beam
  • Systemic
• Immunotherapy      
  • Durvalumab
  • Nivolumab
  • Atezolizumab
  • Pembrolizumab
  • Other immunotherapies
• Targeted Therapy    
  • Bevacizumab
  • Dabrafenib/Trametinib
  • Erlotinib hydrochloride
  • Osimertinib
  • Other targeted therapies
• Chemotherapy         
• Other therapies       

By End-user, 2018 - 2032 (USD Million)

• Hospitals
• Specialty clinics
• Homecare
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa